Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg) | Abstract

Asploro Journal of Biomedical and Clinical Case Reports

Asploro Journal of Biomedical and Clinical Case Reports

ISSN: 2582-0370

Article Type: Case Report

DOI: 10.36502/2023/ASJBCCR.6303

Asp Biomed Clin Case Rep. 2023 Jun 12;6(2):116-23

Masaki Okada1, Hiroshi Bando1,2ID*, Noboru Iwatsuki1, Kazuki Sakamoto1, Tomoya Ogawa1
1Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan
2Tokushima University/Medical research, Tokushima, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 15 May 2023; Accepted date: 06 June 2023; Published date: 12 June 2023

Citation: Okada M, Bando H, Iwatsuki N, Sakamoto K, Ogawa T. Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg). Asp Biomed Clin Case Rep. 2023 Jun 12;6(2):116-23.

Copyright © 2023 Okada M, Bando H, Iwatsuki N, Sakamoto K, Ogawa T. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Low Carbohydrate Diet, Oral Hypoglycemic Agents, Reactive Depression, Adjustment Disorder, Imeglimin (Twymeeg)

Abbreviations: LCD: Low Carbohydrate Diet; OHAs: Oral Hypoglycemic Agents

Abstract

The patient is a 66-year-old female being treated for hypertension. She developed a cerebral vascular accident (CVA) in October 2019, and was subsequently diagnosed with type 2 diabetes (T2D) due to an HbA1c level of 9.8%. She began a low carbohydrate diet (LCD) and started taking oral hypoglycemic agents (OHAs) such as metformin and linagliptin. From July 2021, she occasionally experienced anxiety and palpitations, leading to a diagnosis of reactive depression (adjustment disorder). Despite treatment with etizolam as needed, these symptoms persisted. In December 2022, due to an increase in HbA1c levels to 7.7%, metformin was switched to imeglimin (Twymeeg). By April 2023, her HbA1c had decreased to 6.9%, and she reported a sustained sense of well-being without psychosomatic symptoms.

Facebooktwitterlinkedininstagramflickrfoursquaremail

asploro

Asploro Open Access Publications Limited